NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization12,405 mln
Float164 mln
Earnings Date08/05/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.86
Likely reliable
1-Year Forecast
101
Strong upside
Relative Strength
51
/ 100
In line with market
Debt / Equity
4.22
Highly leveraged
ROE
-68.04
Deeply negative
Business Description
Ionis Pharmaceuticals is a California-based biotech company that develops and sells medicines targeting RNA, a key molecule that carries genetic instructions within the body. The company has several approved treatments on the market for serious conditions including spinal muscular atrophy, hereditary nerve disease, and rare disorders affecting fat metabolism. Ionis also has a broad pipeline of experimental therapies in clinical trials targeting heart disease, liver disease, neurological conditions, and other rare genetic illnesses. To support its research and commercialization efforts, the company works alongside major pharmaceutical partners including GSK, AstraZeneca, Novartis, Roche, and Biogen.